20/20 GeneSystems

20/20 GeneSystems is a biotechnology startup founded in May 2000, based in Rockville, Maryland. The company focuses on developing innovative proteomics products for drug companies, biodefense specialists, and life scientists, with a strong emphasis on collaborations with the National Institutes of Health. Their proprietary diagnostics tests center around personalized medicine, particularly targeting kidney and lung cancer therapeutics, and early detection of lung cancer through a blood test for smokers and former smokers. Additionally, the company is involved in the development of technologies for biological toxin detection. Notably, Equity Crowdfunding investment was secured on May 16, 2020, marking a significant milestone for the company. The company operates within the industries of Big Data, Biotechnology, and Health Care, holding promise in the burgeoning field of personalized medicine and early cancer detection.